Core Viewpoint - The company, Viatris (01873.HK), has announced a board meeting scheduled for August 28, 2025, to consider and approve its interim results for the six months ending June 30, 2025, and to discuss the potential declaration of an interim dividend, if applicable [1]. Group 1 - The board meeting will take place on August 28, 2025 [1] - The meeting will focus on the interim results for the six months ending June 30, 2025 [1] - The company will also consider the proposal for an interim dividend [1]

董事會會議日期 （於開曼群島註冊成立的獲豁免有限公司） （股份代號：1873） 承董事會命 維亞生物科技控股集團（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，本 公 司 將 於二零二 五 年八月二十 八 日（星期四）舉 行 董 事 會 會 議，藉 以（其 中 包 括）考 慮 及 批 准本公司及其附屬公司截至二零二五年六月三十日止六個月之中期業績及其發佈， 並 考 慮 建 議 派 付 中 期 股 息（如 有）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 香港，二零二 五 年八月十 八 日 維亞生物科技控股集團 主席兼首席執行官 毛晨先生 於本公告日期，董事會包括 三 名 執 行 董 事，即 毛 晨 先 生（主 席）、吳 鷹 先 生 及 任 德 林 先 生；兩 名非執行董事，即吳宇挺先生及王暉先生；以及三名獨立非執行董事，即 傅磊先生、李向 榮 女士及王海光先生。 ...

Group 1 - Via Biotechnology (01873) has seen a stock price increase of over 13%, with a cumulative rise of more than 40% in the month [1] - The company’s stock is currently trading at 2.4 HKD, with a trading volume of 50.34 million HKD [1] - The collaboration between Crystal Tech Holdings and DoveTree has set a new record for AI drug discovery orders, indicating a growing demand for AI-assisted drug development from traditional pharmaceutical giants [1] Group 2 - According to Shanxi Securities, the emergence of large orders from multinational corporations (MNCs) validates the profitability of AI pharmaceutical companies through technology licensing and revenue-sharing models [1] - Guoyuan International notes that Via Biotechnology has been involved in AI pharmaceuticals for five years, with AI-related orders now accounting for 12% of new signed orders, showing a growth trend [1] - The company possesses self-developed algorithms and platform capabilities in its AIDD and CADD platforms, leveraging its structural drug development advantages to transition from a computational method focus to AI-driven drug design [1]

Group 1 - The core viewpoint of the article highlights that Viya Bio (01873) has seen a significant increase in its stock price, rising over 13% in a single day and accumulating a total increase of over 40% within the month [1][1][1] - The collaboration between Crystal Technology Holdings and DoveTree has set a new record for AI drug discovery orders, indicating a growing trend in the pharmaceutical industry towards AI-assisted drug development [1][1][1] - Shanxi Securities emphasizes that the large orders from multinational corporations (MNCs) to AI pharmaceutical companies validate the profitability of AI drug companies through technology licensing and revenue-sharing models, reflecting a strong demand from traditional pharmaceutical giants for AI-assisted R&D [1][1][1] Group 2 - According to Guoyuan International, Viya Bio has been investing in AI drug development for the past five years, with AI-related orders now accounting for 12% of new signed orders, showing a positive growth trend [1][1][1] - The company possesses self-developed algorithms and platform capabilities through its AIDD and CADD platforms, along with experience in developing various drug forms, leveraging its structural drug development advantages [1][1][1] - Viya is transitioning from a phase where computational methods empower various stages of drug development to a new phase driven by AI in drug design, aiming to change the paradigm of drug design [1][1][1]

Core Insights - The stock price of Via Biotechnology (01873) increased by 11.32% on August 14, reaching HKD 2.36 per share with a trading volume of HKD 30.83 million [1] - Via Biotechnology provides comprehensive drug development services from research to commercialization for global innovative pharmaceutical companies, including CRO services and CMC/CDMO solutions [1] - As of December 31, 2023, Via Biotechnology has served a total of 2,278 biotech and pharmaceutical clients and incubated 92 biotech startups [1] Financial Performance - For the fiscal year ending 2024, Via Biotechnology reported total revenue of RMB 1.987 billion and a net profit of RMB 167 million [2]

Group 1 - CRO concept stocks have shown significant gains, with notable increases in share prices for companies such as Viatris (up 12.83% to HKD 2.11), Zhaoyan New Drug (up 9.23% to HKD 24.62), and others [1] - WuXi AppTec has raised its full-year sales forecast after reporting a 141.6% year-on-year increase in TIDES business revenue, reaching RMB 5.03 billion in the first half of the year, driven by high demand in the GLP-1 sector [1] - CICC believes that the valuation center for innovative drug sectors has been adjusted upwards, which will enhance domestic new drug R&D demand and increase financing activity for primary innovative drug projects [1] Group 2 - The U.S. Bureau of Labor Statistics reported stable inflation in July, reducing barriers for potential interest rate cuts by the Federal Reserve in September, indicating a recovery trend in overall investment and financing [2] - The domestic market for preclinical CRO, clinical CRO, and CDMO services has stabilized in pricing, with a steady recovery in new orders expected to lead to an industry turnaround [2] - Internationally, the CDMO pricing system remains reasonable, and the impact of high pandemic baselines has been absorbed, suggesting a positive trend for overseas orders [2]

Group 1 - CRO concept stocks have shown significant gains, with notable increases in share prices for companies such as Viatris Bio (+12.83%), Zhaoyan New Drug (+9.23%), and others [1] - WuXi AppTec has raised its full-year sales forecast after reporting a 141.6% year-on-year increase in TIDES business revenue, reaching RMB 5.03 billion in the first half of the year, driven by high demand in the GLP-1 sector [1] - CICC believes that the valuation center for innovative drug sectors has been adjusted upwards, which will enhance domestic new drug R&D demand and increase financing activity for primary innovative drug projects [1] Group 2 - The U.S. Bureau of Labor Statistics reported stable inflation in July, reducing barriers for potential interest rate cuts by the Federal Reserve in September [2] - Overall investment and financing trends are showing signs of recovery, with prices for preclinical CRO, clinical CRO, and CDMO services stabilizing [2] - The international CDMO business maintains a reasonable pricing structure, with the impact of high pandemic baselines now absorbed [2]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01873 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 2,128,434,305 | | 0 | | 2,128,434,305 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 2,128,434,305 | | 0 | | 2,128,434,305 | 第 2 頁 共 10 頁 v 1.1.1 公司名稱: 维亚生物科技控股集团 (「本公司」) (於開曼群島註冊成立的獲豁免有限公司) 呈交日期: ...

Market Performance - The Hong Kong stock market showed mixed performance with the Hang Seng Index rising by 0.68% to 25,562.13 points, while the Tech Index fell by 0.24% to 5,664.02 points, and the National Enterprises Index increased by 0.29% to 9,177.15 points [2][3]. Hang Seng Index Movement - The Hang Seng Index reached a high of 25,660.54 points in the morning but maintained a volatile pattern before closing slightly higher [4]. Sector Performance - Insurance, pharmaceuticals, and brokerage stocks saw collective strength, while coal, shipping, and photovoltaic stocks experienced adjustments [5]. Insurance Sector Strength - Major insurance stocks like AIA Group (up 4.96%), China Pacific Insurance (up 3.91%), and Ping An Insurance (up 3.49%) saw significant gains due to a favorable assessment of life insurance reserve interest rates, which are expected to lower the new business liability costs for insurers [6][7]. Pharmaceutical Sector Boost - Pharmaceutical stocks surged, with companies like Fonda Holdings (up 10.39%), Zhaoyan New Drug (up 6.76%), and Via Biotechnology (up 5.45%) benefiting from overseas licensing deals, including a notable $12.5 billion collaboration between Hengrui Medicine and GlaxoSmithKline [8][9]. Brokerage Sector Gains - Brokerage stocks such as Guotai Junan International (up 9.45%), Shenwan Hongyuan Hong Kong (up 7.32%), and Xingzheng International (up 5.08%) experienced strong performance, likely influenced by the upcoming implementation of the Stablecoin Regulation in Hong Kong [11][13]. Weakness in Cyclical Stocks - Coal, shipping, and photovoltaic stocks faced declines, with companies like Feishang Non-Ferrous Coal (down 15.28%) and COSCO Shipping Ports (down 10.99%) leading the downturn due to falling commodity prices in the futures market [14][18]. Individual Stock Movements - Xuanwu Cloud saw a significant increase of 28% following a strategic partnership with LG Uplus, while Zhejiang United Investment surged by 116.67% on expectations of turning a profit by April 2025 [23][24].

Group 1 - The Hong Kong pharmaceutical stocks showed a strong performance, with several companies experiencing significant gains [1] - Baset Pharmaceutical (02616.HK) increased by 9.86%, indicating a robust market response [1] - Other notable gainers included Charoen Pokphand International (03839.HK) with a rise of 7.06%, Sanofi Pharmaceutical (02257.HK) up by 6.93%, and Weiya Biotechnology (01873.HK) which saw a 5.80% increase [1]